Ligand Pharmaceuticals Announces License and Supply Agreements With Novartis Pharma
Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in its license and supply agreements with Novartis for the development and global commercialization of Captisol-enabled trametinib. Under the agreement, Ligand is eligible to receive a license fee, royalty payments on future net sales, and revenue from Captisol sales.
Novartis is a pharmaceutical company that focuses on researching and developing prescription drug treatments for diseases. Ligand is a biopharmaceutical company that focuses on developing and or acquiring technologies that help pharmaceutical companies in discovering and creating medicines. Read the press release.
San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.